|
|
|
|
||
Novartis signs deal with Britain's NHS for new cholesterol drug LeqvioNovartis signs deal with Britain's NHS for new cholesterol drug LeqvioREUTERS 7:01 PM ET 8/31/2021 The agreement, whose value was not disclosed, will help with wide access to the Swiss drugmaker's medicine through The deal, which builds on a pact signed in 2020 https://www.reuters.com/article/instant-article/idUKKBN1ZC1ZR, is a win for Novartis after U.S. authorities last year declined https://www.reuters.com/article/novartis-fda-idINKBN28T0L0 to approve the drug, which the drugmaker bought in 2019 for nearly About 300,000 patients at high risk of a second cardiovascular incident are expected to be treated with the medicine over three years, Novartis said on Wednesday. Heart disease is a big killer in Leqvio, whose chemical generic name is inclisiran, is a twice-yearly injection that targets "bad cholesterol," a culprit behind heart attacks and strokes, and has been approved in It is an add-on therapy for those patients whose cholesterol levels do not respond adequately to statins. "Having faster and broader access to a medicine like inclisiran ... is a hugely positive milestone in patient care," said Around 7.6 million Britons have heart and circulatory diseases, which account for about a quarter of all deaths annually in the country, according to the |
return to message board, top of board |